SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122355
Filing Date
2024-11-06
Accepted
2024-11-06 16:20:16
Documents
70
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-20240930.htm   iXBRL 10-Q 2305607
2 EX-10.2 trvi-ex10_2.htm EX-10.2 121687
3 EX-10.3 trvi-ex10_3.htm EX-10.3 40043
4 EX-31.1 trvi-ex31_1.htm EX-31.1 15231
5 EX-31.2 trvi-ex31_2.htm EX-31.2 15205
6 EX-32.1 trvi-ex32_1.htm EX-32.1 10007
7 EX-32.2 trvi-ex32_2.htm EX-32.2 9967
8 GRAPHIC img65733204_0.jpg GRAPHIC 10976
9 GRAPHIC img66656725_0.jpg GRAPHIC 40168
  Complete submission text file 0000950170-24-122355.txt   9062784

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20240930.xsd EX-101.SCH 1161071
73 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20240930_htm.xml XML 1514738
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 241431328
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)